Histone deacetylase inhibitors induce cell cycle arrest and apoptosis in tumor cells and are, therefore, promising anticancer drugs. The cyclin-dependent kinase inhibitor p21 is activated in histone deacetylase (HDAC) inhibitor-treated tumor cells, and its growth-inhibitory function contributes to the anti-tumorigenic effect of HDAC inhibitors. We show here that induction of p21 by trichostatin A involves MAP kinase signaling. Activation of the MAP kinase signaling pathway by growth factors or stress signals results in histone H3 serine 10 phosphorylation at the p21 promoter and is crucial for acetylation of the neighboring lysine 14 and recruitment of activated RNA polymerase II in response to trichostatin A treatment. In non-induced cells, the protein phosphatase PP2A is associated with the p21 gene and counteracts its activation. Induction of p21 is linked to simultaneous acetylation and phosphorylation of histone H3. The dual modification mark H3S10phK14ac at the activated p21 promoter is recognized by the phospho-binding protein 14-3-3, which protects the phosphoacetylation mark from being processed by PP2A. Taken together we have revealed a cross-talk of reversible phosphorylation and acetylation signals that controls the activation of p21 by HDAC inhibitors and identify the phosphatase PP2A as chromatin-associated transcriptional repressor in mammalian cells.Post-translational modifications of histones, such as acetylation, methylation, phosphorylation, and sumoylation play important roles in the regulation of chromatin accessibility and gene expression. The transformation of a differentiated resting cell into a highly proliferative tumor cell is accompanied by a severe change of the gene expression profile, which in turn is the direct consequence of acquired/accumulated tumor suppressor and oncogene mutations. In addition to these genetic alterations, epigenetic alterations are also involved in the development of cancer. These include covalent post-translational modifications of histones and changes in the methylation status of cytosines within CpG islands (1, 2). Therefore, compounds that target these epigenetic changes are of potential interest for anti-tumor therapies. Indeed, histone deacetylase (HDAC) 5 inhibitors have been shown to induce cell cycle arrest, differentiation, or apoptosis in tumor cells and are, therefore, promising anti-tumor drugs (3-5).One of the genes that is activated by different HDAC inhibitors encodes the cyclin-dependent kinase (CDK) inhibitor p21 cip1/waf1 (referred to as p21 thereafter) (3, 4). The p21 protein is a member of the CIP/KIP family of cyclin-dependent kinase inhibitors consisting of p21, p27, and p57. The different members of the CIP/KIP family share a conserved region at the N terminus that is required and sufficient for the inhibition of cyclin-Cdk complexes (6, 7). The p21 protein preferentially inactivates cyclin E/Cdk2 complexes, thereby blocking the inactivating phosphorylation of pRb, which represses genes important for S phase entry. In addition, p21 ...